Synthetic triterpenoids show promise in preventing colitis-associated colon cancer

Researchers from Case Western Reserve and Dartmouth show the small antioxidant molecules suppress colon cancer onset

2014-06-24

(Press-News.org) Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for supressing colon cancer associated with colitis. These findings, published in an early June edition of the Journal of Clinical Investigation, offer hope that physicians ultimately will be able to reduce dramatically the number of sufferers of this inflammatory bowel disease (IBD) who go on to develop colon cancer.

The molecules, known as synthetic triterpenoids, appear to achieve their positive effect in two ways. First, they impede inflammation, often a flashpoint that contributes to the development of colon cancer. Second, they increase 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a gene product that is known at high levels to protect against colon cancer. The oral administration of synthetic triterpenoids showed such success in mice that the researchers believe that clinical trials could demonstrate their efficacy in chemoprevention — that is, the administration of medicine to stop or delay the onset of cancer, rather than treat it.

"Patients with inflammatory bowel disease have a 10-fold greater risk of colon cancer, placing it among the top three high-risk conditions for colorectal cancer," said senior author and hematologist/oncologist John Letterio, MD, professor of pediatrics, Case Western Reserve University School of Medicine, and director of the Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital. "Common epithelial cancers develop over a period of years, even decades, in populations at high risk due to genetic predisposition, so chemoprevention strategies could delay, or even halt, onset of clinically evident colon cancer."

Joining Letterio in this investigation was Michael B. Sporn, MD, professor of pharmacology and toxicology, Dartmouth Medical School, who first coined the term "chemoprevention" nearly four decades ago and has investigated synthesized triterpenoids since 1995, demonstrating their effectiveness against epithelial cancers. Sporn collaborates in scientific investigation with leading physicians throughout the country, and Letterio's collaboration with Sporn was a natural because the two worked together when Letterio was a post-doctoral fellow. Colleague Sanford Markowitz, MD, PhD, Ingalls Professor of Cancer Genetics at Case Western Reserve School of Medicine, served an important role in this investigation because of his expertise as the innovator who first characterized 15-PGDH, an important tumor suppressor and natural anti-inflammatory.

"We have been intrigued by recent findings that inflammatory cytokines, such as TNF-alpha, hinder the expression of 15-PGDH," Letterio said. "We found that triterpenoids could reverse the inflammatory process by allowing 15-PGDH expression to resume. Triterpenoids also impede expression of the cyclooxygenase-2 (COX-2), an enzyme known to fuel inflammation. Between reversing the effects of TNF-alpha and of COX-2, this class of small molecules might suppress colitis-associated colon cancer."

In mice genetically engineered toward proneness for inflammation-driven intestinal neoplasia, oral administered triterpenoids increased the survival of the mice. Triterpenoid molecules also suppressed intestinal epithelial neoplasia by decreasing production of inflammatory mediators and increasing expression of colon-cancer-suppressing 15-PGDH.

Investigators also found that triterpenoids administered to normal mice prevented their development of inflammation and colon cancer, despite their exposure to carcinogens known to cause these two conditions. In addition, they discovered that triterpenoids trigger epithelial cells' responses to TGF-beta, a signaling pathway known to activate 15-PGDH.

"Two observations are particularly significant in this study," Letterio said. "First, our studies in mice demonstrate a cancer chemoprevention effect with triterpenoids. Second, our data also show that the production of 15-PGDH in mice depended on the presence of an intact TGF-beta signalling pathway. This pathway ensures that internal conditions remain relatively constant in intestinal mucosa, both in the regulation of epithelial cell differentiation and development of inducible regulatory T cells to fend off cancer."

The research team next will focus on assessing the effect of triterpenoids for models of IBD and colon cancer that are not related to colitis. Investigators also want to explore whether plant-derived natural triterpenoids with similar properties to laboratory-produced synthetic triterpenoids might offer a comparable benefit.

"The argument is strong for pursuing human trials in cancer chemoprevention with triterpenoids," Letterio said. "There are many questions about safety, efficacy, intermittent vs. continuous administration, and synthetic vs. natural triterpenoid. Carefully designed clinical trials and a collaborative approach between industry and academics will be needed to address these questions."

Markowitz concurs and additionally addresses the significance of findings in this latest investigation.

"Colon cancer is among the most feared consequences of long-term ulcerative colitis," he said. "Even with intense surveillance of the colon by colonoscopy and random biopsies, development of cancer is not always caught in time. The finding that synthetic triterpenoids can prevent colon cancer in the mouse model is the first true advance in this field and opens up a novel opportunity for developing new drugs for use in human patients."

INFORMATION: This work was supported by National Institutes of Health grants RO1 CA168586A and R01 CA78814.

About Case Comprehensive Cancer Center Case Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center located at Case Western Reserve University. The center, which has been continuously funded since 1987, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve, University Hospitals (UH) Case Medical Center and the Cleveland Clinic. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. It is led by Stanton Gerson, MD, Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the National Center for Regenerative Medicine, Case Western Reserve, and director of the Seidman Cancer Center at UH Case Medical Center.

About Case Western Reserve University School of Medicine Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation's top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School's innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.

Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report's "Guide to Graduate Education."

The School of Medicine's primary affiliate is University Hospitals Case Medical Center and is additionally affiliated with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. http://casemed.case.edu

ELSE PRESS RELEASES FROM THIS DATE:

Helpful bouncing babies show that moving together to music builds bonds

2014-06-24

HAMILTON, ON, June 24, 2014 — Whether they march in unison, row in the same boat or dance to the same song, people who move in time with one another are more likely to bond and work together afterward. It's a principle established by previous studies, but now researchers at McMaster University have shown that moving in time with others even affects the social behavior of babies who have barely learned to walk. "Moving in sync with others is an important part of musical activities," says Laura Cirelli, lead author of a paper now posted online and scheduled to appear ...

Food scientists working to diminish, mask bitter tastes in foods

2014-06-24

Food scientists are working to block, mask and/or distract from bitter tastes in foods to make them more palatable to consumers, many of whom are genetically sensitive to bitter tastes, according to a new presentation at the 2014 Institute of Food Technologists (IFT) Annual Meeting & Food Expo® in New Orleans. "Many factors go into why we eat what we do," said John Hayes, PhD, assistant professor of food science and director of the Sensory Evaluation Center at Pennsylvania State University, with taste consistently ranking as number one. There's also "a huge variability ...

Not everyone wants cheering up, new study suggests

2014-06-24

You may want to rethink cheering up your friends who have low self-esteem because chances are they don't want to hear it. People with low self-esteem have overly negative views of themselves, and often interpret critical feedback, romantic rejections, or unsuccessful job applications as evidence of their general unworthiness. A new study from researchers at the University of Waterloo and Wilfrid Laurier University found that they likely don't want you to try to boost their spirits. "People with low self-esteem want their loved ones to see them as they see themselves. ...

Metal particles in solids aren't as fixed as they seem, new memristor study shows

2014-06-24

ANN ARBOR—In work that unmasks some of the magic behind memristors and "resistive random access memory," or RRAM—cutting-edge computer components that combine logic and memory functions—researchers have shown that the metal particles in memristors don't stay put as previously thought. The findings have broad implications for the semiconductor industry and beyond. They show, for the first time, exactly how some memristors remember. "Most people have thought you can't move metal particles in a solid material," said Wei Lu, associate professor of electrical and computer ...

Researchers at Intermountain Medical Center develop new smartphone technology and app to diagnose and monitor adrenal gland diseases

2014-06-24

Diseases of the adrenal gland have long been difficult to diagnose. But now, researchers have found an affordable and easy way to diagnose and monitor endocrine diseases of the adrenal gland by using saliva and a smartphone. Researchers at Intermountain Medical Center in Murray, Utah, have developed new smartphone technology to help screen patients for a number of adrenal gland diseases, including Cushing's syndrome. The new tool also helps to identify adrenal insufficiency, monitor cortisol replacement and assess physiologic changes in adrenal function. Adrenal diseases ...

To advance care for patients with brain metastases: Reject five myths

2014-06-24

New York, NY – A blue-ribbon team of national experts on brain cancer says that professional pessimism and out-of-date "myths," rather than current science, are guiding -- and compromising -- the care of patients with cancers that spread to the brain. In a special article published in the July issue of Neurosurgery, the team, led by an NYU Langone Medical Center neurosurgeon, argues that many past, key clinical trials were designed with out-of-date assumptions and the tendency of some physicians to "lump together" brain metastases of diverse kinds of cancer, often results ...

Mayo Clinic researchers say gene in brain linked to kidney cancer

2014-06-24

JACKSONVILLE, Fla. — A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. Their study, published in Cancer Research, reveals that the gene NPTX2, plays an essential role in this cancer type, which is resistant to common chemotherapy and has a five-year overall survival rate of less than 10 percent in patients with metastatic disease. MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic ...

Virus kills triple negative breast cancer cells, tumor cells in mice

2014-06-24

A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer may lead to new treatments for breast cancer. Adeno-associated virus type 2 (AAV2) infects humans but is not known to cause sickness. In prior studies, the researchers tested the virus on a variety of breast cancers that represent degrees of aggressiveness and on human papillomavirus-positive cervical cancer cells. The virus initiated apoptosis -- ...

Morphable surfaces could cut air resistance

2014-06-24

CAMBRIDGE, Mass-- There is a story about how the modern golf ball, with its dimpled surface, came to be: In the mid-1800s, it is said, new golf balls were smooth, but became dimpled over time as impacts left permanent dents. Smooth new balls were typically used for tournament play, but in one match, a player ran short, had to use an old, dented one, and realized that he could drive this dimpled ball much further than a smooth one. Whether that story is true or not, testing over the years has proved that a golf ball's irregular surface really does dramatically increase ...

CNIO researcher Ana Losada revises the role of cohesin in cancer

2014-06-24

Massive sequencing of cancer genomes brings to light new genes every day that could be involved in the process of tumour formation. A good example of this is cohesin, a ring-shaped protein complex that embraces DNA to control cell division. Just a few months ago, and after several studies in the same direction, the sequencing of thousands of tumour samples identified the STAG2 gene—whose product forms part of cohesin—as one of the most frequently mutated genes in several types of cancer such as bladder cancer and melanoma. The challenge now is to understand the link between ...

Synthetic triterpenoids show promise in preventing colitis-associated colon cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: